Extracellular Vesicle Therapy for Type 1 Diabetes

Setareh Soltani; Kamran Mansouri; Mohammad Sajad Emami Aleagha; Narges Moasefi; Niloofar Yavari; Seyed Kazem Shakouri; Sara Notararigo; Ali Shojaeian; Flemming Pociot; Reza Yarani; Reza Yarani

doi:10.3389/fimmu.2022.865782

Frontiers in Immunology (Apr 2022)

Extracellular Vesicle Therapy for Type 1 Diabetes

Setareh Soltani,
Kamran Mansouri,
Mohammad Sajad Emami Aleagha,
Narges Moasefi,
Niloofar Yavari,
Seyed Kazem Shakouri,
Sara Notararigo,
Ali Shojaeian,
Flemming Pociot,
Reza Yarani,
Reza Yarani

Affiliations

Setareh Soltani: Clinical Research Development Center, Taleghani and Imam Ali Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran
Kamran Mansouri: Medical Biology Research Center, Health Technology Institute, University of Medical Sciences, Kermanshah, Iran
Mohammad Sajad Emami Aleagha: Medical Technology Research Center (MTRC), School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran
Narges Moasefi: Medical Technology Research Center (MTRC), School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran
Niloofar Yavari: Department of Cellular and Molecular Medicine, The Panum Institute, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Seyed Kazem Shakouri: Physical Medicine and Rehabilitation Research Center, Aging Research Institute, Tabriz University of Medical Sciences, Tabriz, Iran
Sara Notararigo: Instituto de Investigación Sanitaria de Santiago (IDIS), Complejo Hospitalario Universitario de Santiago (CHUS), Servicio Gallego de Salud (SERGAS), Santiago de Compostela, Spain
Ali Shojaeian: Research Center for Molecular Medicine, Hamadan University of Medical Sciences, Hamadan, Iran
Flemming Pociot: Translational Type 1 Diabetes Research, Department of Clinical, Research, Steno Diabetes Center Copenhagen, Gentofte, Denmark
Reza Yarani: Translational Type 1 Diabetes Research, Department of Clinical, Research, Steno Diabetes Center Copenhagen, Gentofte, Denmark
Reza Yarani: Interventional Regenerative Medicine and Imaging Laboratory, Department of Radiology, Stanford University School of Medicine, Palo Alto, CA, United States

DOI: https://doi.org/10.3389/fimmu.2022.865782
Journal volume & issue: Vol. 13

Abstract

Read online

Type 1 diabetes (T1D) is a chronic disorder characterized by immune-mediated destruction of pancreatic insulin-producing β-cells. The primary treatment for T1D is multiple daily insulin injections to control blood sugar levels. Cell-free delivery packets with therapeutic properties, extracellular vesicles (EVs), mainly from stem cells, have recently gained considerable attention for disease treatments. EVs provide a great potential to treat T1D ascribed to their regenerative, anti-inflammatory, and immunomodulatory effects. Here, we summarize the latest EV applications for T1D treatment and highlight opportunities for further investigation.

Published in Frontiers in Immunology

ISSN: 1664-3224 (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Immunologic diseases. Allergy
Website: http://journal.frontiersin.org/journal/immunology

About the journal

Abstract

Keywords